214 related articles for article (PubMed ID: 19605376)
21. Safety and efficacy of recombinant activated factor VII in nonhemophilia children with severe or life-threatening bleeding: a report from the SeveNBleeP registry.
Blatný J; Mathew P; Monagle P; Ovesna P; Fiamoli V
Blood Coagul Fibrinolysis; 2014 Jun; 25(4):326-32. PubMed ID: 24389586
[TBL] [Abstract][Full Text] [Related]
22. The use of recombinant activated factor VII in trauma patients: Experience from the Australian and New Zealand haemostasis registry.
Cameron P; Phillips L; Balogh Z; Joseph A; Pearce A; Parr M; Jankelowitz G
Injury; 2007 Sep; 38(9):1030-8. PubMed ID: 17706654
[TBL] [Abstract][Full Text] [Related]
23. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis.
Gelsomino S; Lorusso R; Romagnoli S; Bevilacqua S; De Cicco G; Billè G; Stefàno P; Gensini GF
Eur J Cardiothorac Surg; 2008 Jan; 33(1):64-71. PubMed ID: 17996457
[TBL] [Abstract][Full Text] [Related]
24. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
[TBL] [Abstract][Full Text] [Related]
25. [Activated recombinant factor VII (Novoseven) in multiple trauma patients: an outcome analysis].
Grinţescu I; Tulbure D; Mirea L
Chirurgia (Bucur); 2006; 101(6):615-24. PubMed ID: 17283837
[TBL] [Abstract][Full Text] [Related]
26. Pediatric off-label use of recombinant factor VIIa.
Alten JA; Benner K; Green K; Toole B; Tofil NM; Winkler MK
Pediatrics; 2009 Mar; 123(3):1066-72. PubMed ID: 19255041
[TBL] [Abstract][Full Text] [Related]
27. Recombinant activated factor VII use in critically ill infants with active hemorrhage.
Jen H; Shew S
J Pediatr Surg; 2008 Dec; 43(12):2235-8. PubMed ID: 19040942
[TBL] [Abstract][Full Text] [Related]
28. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
29. Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.
Bowman LJ; Uber WE; Stroud MR; Christiansen LR; Lazarchick J; Crumbley AJ; Kratz JM; Toole JM; Crawford FA; Ikonomidis JS
Ann Thorac Surg; 2008 May; 85(5):1669-76; discussion 1676-7. PubMed ID: 18442563
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience.
Payne EM; Brett SJ; Laffan MA
Blood Coagul Fibrinolysis; 2006 Jul; 17(5):397-402. PubMed ID: 16788316
[TBL] [Abstract][Full Text] [Related]
31. Recombinant activated coagulation factor VII and bleeding trauma patients.
Rizoli SB; Nascimento B; Osman F; Netto FS; Kiss A; Callum J; Brenneman FD; Tremblay L; Tien HC
J Trauma; 2006 Dec; 61(6):1419-25. PubMed ID: 17159685
[TBL] [Abstract][Full Text] [Related]
32. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.
Brady KM; Easley RB; Tobias JD
Paediatr Anaesth; 2006 Oct; 16(10):1042-6. PubMed ID: 16972833
[TBL] [Abstract][Full Text] [Related]
33. Adequacy of hemostatic resuscitation improves therapeutic efficacy of recombinant activated factor VII and reduces reexploration rate for bleeding in postoperative cardiac surgery patients with refractory hemorrhage.
Feih JT; Juul JJ; G Rinka JR; Baumann Kreuziger LM; Pagel PS; Tawil JN
Ann Card Anaesth; 2019; 22(4):388-393. PubMed ID: 31621674
[TBL] [Abstract][Full Text] [Related]
34. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion.
Spinella PC; Perkins JG; McLaughlin DF; Niles SE; Grathwohl KW; Beekley AC; Salinas J; Mehta S; Wade CE; Holcomb JB
J Trauma; 2008 Feb; 64(2):286-93; discussion 293-4. PubMed ID: 18301188
[TBL] [Abstract][Full Text] [Related]
35. Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, efficacy, and safety outcomes.
Masud F; Bostan F; Chi E; Pass SE; Samir H; Stuebing K; Liebl MG
J Cardiothorac Vasc Anesth; 2009 Feb; 23(1):28-33. PubMed ID: 18948033
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery.
Gill R; Herbertson M; Vuylsteke A; Olsen PS; von Heymann C; Mythen M; Sellke F; Booth F; Schmidt TA
Circulation; 2009 Jul; 120(1):21-7. PubMed ID: 19546387
[TBL] [Abstract][Full Text] [Related]
37. Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7).
Hacquard M; Durand M; Lecompte T; Boini S; Briançon S; Carteaux JP
Eur J Cardiothorac Surg; 2011 Dec; 40(6):1320-7. PubMed ID: 21550261
[TBL] [Abstract][Full Text] [Related]
38. Recombinant Activated Factor VII Significantly Reduces Transfusion Requirements in Cardiothoracic Surgery.
Omar HR; Enten G; Karlnoski R; Ching YH; Mangar D; Camporesi EM
Drugs R D; 2015 Jun; 15(2):187-94. PubMed ID: 25862216
[TBL] [Abstract][Full Text] [Related]
39. Prolonged prothrombin time after recombinant activated factor VII therapy in critically bleeding trauma patients is associated with adverse outcomes.
McMullin NR; Wade CE; Holcomb JB; Nielsen TG; Rossaint R; Riou B; Rizoli SB; Kluger Y; Choong PI; Warren B; Tortella BJ; Boffard KD;
J Trauma; 2010 Jul; 69(1):60-9. PubMed ID: 20622579
[TBL] [Abstract][Full Text] [Related]
40. Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.
Tomita E; Takase H; Tajima K; Suematsu Y
Asian Cardiovasc Thorac Ann; 2017 Feb; 25(2):99-104. PubMed ID: 28114794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
